Management of Erythrodermic Psoriasis: Evidence‑Based Recommendations

Triggers and Initial Assessment

Abrupt withdrawal of systemic corticosteroids can precipitate erythrodermic transformation; clinicians should identify recent steroid tapering as a key trigger. [1][2]

Cyclosporine is recommended as the rapid‑acting first‑line agent for unstable erythrodermic psoriasis.
- Dose: 3–5 mg/kg/day divided twice daily. 1
- Expected clinical response within ≈ 3 weeks. [3][4]
- Contraindicated in patients with abnormal renal function, uncontrolled hypertension, or a history of malignancy. [3][4]
- Monitoring protocol: blood pressure and serum creatinine every 2 weeks for the first 3 months, then monthly. Reduce dose if creatinine rises >30 % from baseline. [1][2]

Methotrexate is advised for maintenance of stable erythrodermic psoriasis.
- Dose: 7.5–25 mg weekly, not exceeding 0.2 mg/kg. [3][5]6
- Clinical improvement typically observed within ≈ 2 weeks. [3][4]
- Mandatory folic‑acid supplementation to mitigate gastrointestinal and hepatic adverse effects (American Academy of Dermatology). 6
- Contraindications include pregnancy, breastfeeding, significant hepatic disease, and hematologic abnormalities (anemia, leukopenia, thrombocytopenia). [3][4]
- Monitoring: weekly complete blood count, liver‑function tests, and serum creatinine initially; thereafter every 1–2 months when stable. Baseline and annual liver‑fibrosis screening if risk factors persist. [3][5][7][6]
Acitretin (retinoid) is an alternative for stable disease when methotrexate is unsuitable.
- Dose: start at 0.75 mg/kg/day, titrate to 0.5 mg/kg/day. [8][9]
- Expected response time ≈ 6 weeks. [3][4]
- Critical contraindication: pregnancy or desire to conceive within 2 years after discontinuation because of prolonged teratogenic risk. [8][1]5

Methotrexate interacts adversely with alcohol, non‑steroidal anti‑inflammatory drugs, co‑trimoxazole, trimethoprim, and salicylates; avoid concurrent use. [3][5]10
Cyclosporine has significant interactions with aminoglycosides, amphotericin, trimethoprim, ketoconazole, and NSAIDs; these agents should be avoided or used with caution. [1][9]10

Methotrexate requires effective contraception for both men and women during therapy and for at least 3 months after cessation (American Academy of Dermatology). 6
Retinoids (Acitretin) demand reliable contraception for women for a minimum of 2 years after stopping treatment (National Psoriasis Foundation). [8][1]2

Systemic corticosteroids must not be abruptly discontinued, as this precipitates erythrodermic flare‑ups. [1][2]10
Indications for short‑term systemic corticosteroids in erythrodermic psoriasis are limited to:
- Persistent, uncontrollable erythroderma causing metabolic complications,
- Generalized pustular psoriasis when other agents are contraindicated, and
- Hyper‑acute psoriatic polyarthritis threatening irreversible joint damage. (National Psoriasis Foundation consensus) [1][2]10

Salicylic acid should not be combined with calcipotriene because the acidic environment inactivates calcipotriene (American Academy of Dermatology). 11